收费全文 | 1388篇 |
免费 | 109篇 |
国内免费 | 143篇 |
2023年 | 21篇 |
2022年 | 35篇 |
2021年 | 85篇 |
2020年 | 85篇 |
2019年 | 109篇 |
2018年 | 66篇 |
2017年 | 56篇 |
2016年 | 46篇 |
2015年 | 86篇 |
2014年 | 92篇 |
2013年 | 108篇 |
2012年 | 114篇 |
2011年 | 112篇 |
2010年 | 73篇 |
2009年 | 58篇 |
2008年 | 64篇 |
2007年 | 55篇 |
2006年 | 46篇 |
2005年 | 39篇 |
2004年 | 36篇 |
2003年 | 38篇 |
2002年 | 25篇 |
2001年 | 20篇 |
2000年 | 15篇 |
1999年 | 8篇 |
1998年 | 11篇 |
1997年 | 5篇 |
1996年 | 5篇 |
1994年 | 9篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 9篇 |
1990年 | 9篇 |
1989年 | 4篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1986年 | 6篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 9篇 |
1981年 | 4篇 |
1980年 | 9篇 |
1979年 | 10篇 |
1978年 | 3篇 |
1977年 | 6篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1974年 | 6篇 |
1972年 | 4篇 |
Glioblastoma multiform (GBM) is known as an aggressive glial neoplasm. Recently incorporation of mesenchymal stem cells with anti-tumor drugs have been used due to lack of immunological responses and their easy accessibility. In this study, we have investigated the anti-proliferative and apoptotic activity of atorvastatin (Ator) in combination of mesenchymal stem cells (MSCs) on GBM cells in vitro and in vivo. The MSCs isolated from rats and characterized for their multi-potency features. The anti-proliferative and migration inhibition of Ator and MSCs were evaluated by MTT and scratch migration assays. The annexin/PI percentage and cell cycle arrest of treated C6 cells were evaluated until 72 h incubation. The animal model was established via injection of C6 cells in the brain of rats and subsequent injection of Ator each 3 days and single injection of MSCs until 12 days. The growth rate, migrational phenotype and cell cycle progression of C6 cells decreased and inhibited by the interplay of different factors in the presence of Ator and MSCs. The effect of Ator and MSCs on animal models displayed a significant reduction in tumor size and weight. Furthermore, histopathology evaluation proved low hypercellularity and mitosis index as well as mild invasive tumor cells for perivascular cuffing without pseudopalisading necrosis and small delicate vessels in Ator?+?MSCs condition. In summary, Ator and MSCs delivery to GBM model provides an effective strategy for targeted therapy of brain tumor.
相似文献In the present study, radiation doses and cancer risks resulting from abdominopelvic radiotherapy planning computed tomography (RP-CT) and abdominopelvic diagnostic CT (DG-CT) examinations are compared. Two groups of patients who underwent abdominopelvic CT scans with RP-CT (n = 50) and DG-CT (n = 50) voluntarily participated in this study. The two groups of patients had approximately similar demographic features including mass, height, body mass index, sex, and age. Radiation dose parameters included CTDIvol, dose–length product, scan length, effective tube current, and pitch factor, all taken from the CT scanner console. The ImPACT software was used to calculate the patient-specific radiation doses. The risks of cancer incidence and mortality were estimated based on the BEIR VII report of the US National Research Council. In the RP-CT group, the mean ± standard deviation of cancer incidence risk for all cancers, leukemia, and all solid cancers was 621.58 ± 214.76, 101.59 ± 27.15, and 516.60 ± 189.01 cancers per 100,000 individuals, respectively, for male patients. For female patients, the corresponding risks were 742.71 ± 292.35, 74.26 ± 20.26, and 667.03 ± 275.67 cancers per 100,000 individuals, respectively. In contrast, for DG-CT cancer incidence risks were 470.22 ± 170.07, 78.23 ± 18.22, and 390.25 ± 152.82 cancers per 100,000 individuals for male patients, while they were 638.65 ± 232.93, 62.14 ± 13.74, and 575.73 ± 221.21 cancers per 100,000 individuals for female patients. Cancer incidence and mortality risks were greater for RP-CT than for DG-CT scans. It is concluded that the various protocols of abdominopelvic CT scans, especially the RP-CT scans, should be optimized with respect to the radiation doses associated with these scans.
相似文献